Moderna, Inc. (MRNA) EPS CAGR:-29.88%(TTM)
The eps cagr for Moderna, Inc. (MRNA) is -29.88% over the latest trailing 12-month period. EPS CAGR uses precomputed diluted earnings history where available.
The eps cagr for Moderna, Inc. (MRNA) stock is -29.88% over the past 12 months. EPS (Earnings Per Share) CAGR measures how Moderna, Inc.'s earnings per share have grown. This is a key metric for valuation and reflects profitability on a per-share basis.
MRNA EPS CAGR Chart
Moderna, Inc. (MRNA)
MRNA EPS CAGR History
| Year | Start EPS | End EPS | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $-9.27 | $-7.26 | +$2.01 | +0.00% | N/A |
| 2024 | $-12.34 | $-9.27 | +$3.07 | +0.00% | N/A |
| 2023 | $21.26 | $-12.34 | $-33.60 | -158.04% | N/A |
| 2022 | $30.31 | $21.26 | $-9.05 | -29.86% | -29.86% |
| 2021 | $-1.96 | $30.31 | +$32.27 | +0.00% | N/A |
| 2020 | $-1.55 | $-1.96 | $-0.41 | +0.00% | N/A |
| 2019 | $-1.17 | $-1.55 | $-0.38 | +0.00% | N/A |
| 2018 | $-0.72 | $-1.17 | $-0.45 | +0.00% | N/A |
| 2017 | $-3.79 | $-0.72 | +$3.07 | +0.00% | N/A |
Quarterly EPS — QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $-3.40 | -61.1% | -34.9% |
| Q4 2025 | $-2.11 | -313.7% | +27.5% |
| Q3 2025 | $-0.51 | +76.1% | -1608.9% |
| Q2 2025 | $-2.13 | +15.5% | +36.0% |
| Q1 2025 | $-2.52 | +13.4% | +18.2% |
| Q4 2024 | $-2.91 | -8709.5% | -610.5% |
| Q3 2024 | $0.03 | +101.0% | +100.4% |
| Q2 2024 | $-3.33 | -8.1% | +8.0% |
| Q1 2024 | $-3.08 | -640.4% | -1640.0% |
| Q4 2023 | $0.57 | +106.0% | -85.0% |
| Q3 2023 | $-9.53 | -163.3% | -456.9% |
| Q2 2023 | $-3.62 | -1910.0% | -165.2% |
| Q1 2023 | $0.20 | -94.8% | -97.8% |
| Q4 2022 | $3.81 | +42.7% | -68.3% |
| Q3 2022 | $2.67 | -51.9% | -67.7% |
| Q2 2022 | $5.55 | -38.9% | -19.9% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel